Board Member
Candel Therapeutics, Inc. (CADL)Equibles does not estimate personal net worth.
Get an email with a short summary when Candel Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CADL alertsPaul Peter Tak is recorded as Board Member at Candel Therapeutics, Inc. (CADL) since January 1, 2020 and CEO at Candel Therapeutics, Inc. (CADL). The newest filing on record that lists Paul Peter Tak as CEO and Board Member at Candel Therapeutics, Inc. (CADL) is dated April 29, 2026. The proxy statement of Candel Therapeutics, Inc. reports total compensation of $5,344,561 for Paul Peter Tak in fiscal 2025, including a base salary of $743,592. Disclosed compensation is on record for 6 fiscal years. Paul Peter Tak has spoken on 2 investor events across 1 company, most recently for Candel Therapeutics, Inc. on June 3, 2026. Candel Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Candel Therapeutics, Inc. includes Charles Schoch (CFO), Jason Amello (CFO), Diem Nguyen, Ph.D. (Board Member) and 7 others.
“I had meetings with 18 investors today, and we're even not raising money at the moment. So I lost my voice, so I hope you can still hear me. Candelto Reputex is focused on developing viral immunotherapies for difficult to treat solid tumors.”
“We are pleased to reflect on the extended follow-up results from our Phase 3 clinical trial of aglathimogen, mesadenofac, or aglathimogen, in intermediate to high-risk localized prostate cancer.”
2020-01-01–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
CEO, Board Member
2020-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Candel Therapeutics, Inc. (CADL) | M.D., Ph.D., FMedSci, Chief Executive Officer | $743,592 | $5,344,561 |
| 2024 | Candel Therapeutics, Inc. (CADL) | M.D., Ph.D, FMedSci, Chief Executive Officer | $688,940 | $1,449,222 |
| 2023 | Candel Therapeutics, Inc. (CADL) | M.D., Ph.D, FMedSci, Chief Executive Officer | $670,000 | $1,484,759 |
| 2022 | Candel Therapeutics, Inc. (CADL) | M.D., Ph.D, FMedSci, Chief Executive Officer | $670,000 | $1,844,971 |
| 2021 | Candel Therapeutics, Inc. (CADL) | M.D., Ph.D, FMedSci,Chief Executive Officer | $545,116 | $956,800 |
| 2020 | Candel Therapeutics, Inc. (CADL) | M.D., Ph.D., FMedSci, President and Chief Executive Officer | $134,615 | $2,626,511 |
